U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210125) titled 'Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting' on Sept. 15.
Brief Summary: This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
Study Start Date: Sept. 16
Study Type: INTERVENTIONAL
Condition:
HIV
Intervention:
DRUG: Lenacapavir long-acting
Until recently, only oral formulations of PrEP were available. With the availability of long-acting PrEP injectables, new strategies will need to be developed to deliver this new treatment option....